TG Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio184.75190.66
Forward P/E45.21
P/S Ratio13.1310.34568.84371.9644096.70
P/B Ratio19.4315.0527.0410.4912.91
Price/Tangible Book19.4315.0527.4110.5312.93
Enterprise Value Ratios
EV/Revenue12.879.83535.24322.8242698.06
EV/EBITDA100.79110.20
EV/EBIT100.95111.33
Profitability & Returns
Return on Equity (ROE)0.12%0.12%-1.51%-0.92%-1.00%
Return on Assets (ROA)0.06%0.05%-0.48%-0.43%-0.43%
Return on Invested Capital (ROIC)0.35%1.17%
Return on Capital Employed (ROCE)0.09%0.07%-1.55%-1.10%-0.51%
Leverage & Solvency Ratios
Debt/Equity1.140.691.420.340.08
Debt/EBITDA5.744.82
Liquidity Ratios
Current Ratio6.255.923.165.066.99
Quick Ratio4.855.003.044.836.92
Efficiency Ratios
Asset Turnover0.720.890.010.010.00
Inventory Turnover0.51
Yield & Distribution Ratios
Earnings Yield0.01%0.01%-0.14%-0.14%-0.04%
FCF Yield-0.01%-0.01%-0.11%-0.12%-0.03%
Buyback Yield-0.08%-0.10%-0.02%-0.15%-0.31%